BACKGROUND: The impact of in utero exposure to highly active antiretroviral therapy (HAART) on longitudinal growth of HIV-uninfected infants is unknown. METHODS: The Mashi and Mma Bana PMTCT intervention trials enrolled HIV-infected pregnant women at four sites in Botswana. Breast-fed (BF), HIV-uninfected infants born at 37 weeks or greater were included in this analysis. Weight-for-age (WAZ), length-for-age (LAZ), and weight-for-length (WLZ) z-scores were calculated using World Health Organization Child Growth Standards. Mean z-scores were compared between in utero antiretroviral exposure groups using Student t test, response profiles analysis, and general linear mixed effects modeling. RESULTS: Growth of 619 HAART-exposed and 440 zidovudine-exposed, HIV-uninfected infants was evaluated. Mean birth weights were 3.01 kg for HAART and 3.15 kg for zidovudine-exposed infants (P < 0.001) with lower mean birth WAZ, length-for-age (LAZ), and weight-for-length (WLZ) among HAART-exposed infants (all P < 0.001). HAART-exposed infants had greater improvement in WAZ and weight-for-length (WLZ) from birth through 2 months (P = 0.03, P < 0.001, respectively). The WAZ did not differ between groups from 3 through 6 months (P = 0.26). Length-for-age (LAZ) remained lower in HAART-exposed infants but the incidence of wasting or stunting did not differ between exposure groups. CONCLUSIONS: Lower weights in HAART-exposed uninfected infants at birth were rapidly corrected during the first 6 months of life.
BACKGROUND: The impact of in utero exposure to highly active antiretroviral therapy (HAART) on longitudinal growth of HIV-uninfectedinfants is unknown. METHODS: The Mashi and Mma Bana PMTCT intervention trials enrolled HIV-infected pregnant women at four sites in Botswana. Breast-fed (BF), HIV-uninfectedinfants born at 37 weeks or greater were included in this analysis. Weight-for-age (WAZ), length-for-age (LAZ), and weight-for-length (WLZ) z-scores were calculated using World Health Organization Child Growth Standards. Mean z-scores were compared between in utero antiretroviral exposure groups using Student t test, response profiles analysis, and general linear mixed effects modeling. RESULTS: Growth of 619 HAART-exposed and 440 zidovudine-exposed, HIV-uninfectedinfants was evaluated. Mean birth weights were 3.01 kg for HAART and 3.15 kg for zidovudine-exposed infants (P < 0.001) with lower mean birth WAZ, length-for-age (LAZ), and weight-for-length (WLZ) among HAART-exposed infants (all P < 0.001). HAART-exposed infants had greater improvement in WAZ and weight-for-length (WLZ) from birth through 2 months (P = 0.03, P < 0.001, respectively). The WAZ did not differ between groups from 3 through 6 months (P = 0.26). Length-for-age (LAZ) remained lower in HAART-exposed infants but the incidence of wasting or stunting did not differ between exposure groups. CONCLUSIONS: Lower weights in HAART-exposed uninfected infants at birth were rapidly corrected during the first 6 months of life.
Authors: Edgardo G Szyld; Eduardo M Warley; Laura Freimanis; René Gonin; Pedro E Cahn; Guilherme A Calvet; Geraldo Duarte; Victor H Melo; Jennifer S Read Journal: AIDS Date: 2006-11-28 Impact factor: 4.177
Authors: Roger L Shapiro; Ibou Thior; Peter B Gilbert; Shahin Lockman; Carolyn Wester; Laura M Smeaton; Lisa Stevens; S Jody Heymann; Thumbi Ndung'u; Simani Gaseitsiwe; Vladimir Novitsky; Joseph Makhema; Stephen Lagakos; Max Essex Journal: AIDS Date: 2006-06-12 Impact factor: 4.177
Authors: Ibou Thior; Shahin Lockman; Laura M Smeaton; Roger L Shapiro; Carolyn Wester; S Jody Heymann; Peter B Gilbert; Lisa Stevens; Trevor Peter; Soyeon Kim; Erik van Widenfelt; Claire Moffat; Patrick Ndase; Peter Arimi; Poloko Kebaabetswe; Patson Mazonde; Joseph Makhema; Kenneth McIntosh; Vladimir Novitsky; Tun-Hou Lee; Richard Marlink; Stephen Lagakos; Max Essex Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: R L Shapiro; M D Hughes; A Ogwu; D Kitch; S Lockman; C Moffat; J Makhema; S Moyo; I Thior; K McIntosh; E van Widenfelt; J Leidner; K Powis; A Asmelash; E Tumbare; S Zwerski; U Sharma; E Handelsman; K Mburu; O Jayeoba; E Moko; S Souda; E Lubega; M Akhtar; C Wester; R Tuomola; W Snowden; M Martinez-Tristani; L Mazhani; M Essex Journal: N Engl J Med Date: 2010-06-17 Impact factor: 91.245
Authors: Ruth E Tuomala; David E Shapiro; Lynne M Mofenson; Yvonne Bryson; Mary Culnane; Michael D Hughes; M J O'Sullivan; Gwendolyn Scott; Alice M Stek; Diane Wara; Marc Bulterys Journal: N Engl J Med Date: 2002-06-13 Impact factor: 91.245
Authors: George K Siberry; Paige L Williams; Hermann Mendez; George R Seage; Denise L Jacobson; Rohan Hazra; Kenneth C Rich; Raymond Griner; Katherine Tassiopoulos; Deborah Kacanek; Lynne M Mofenson; Tracie Miller; Linda A DiMeglio; D Heather Watts Journal: AIDS Date: 2012-06-01 Impact factor: 4.177
Authors: Lindsey M Locks; Karim P Manji; Roland Kupka; Enju Liu; Rodrick Kisenge; Christine M McDonald; Said Aboud; Molin Wang; Wafaie W Fawzi; Christopher P Duggan Journal: J Pediatr Date: 2016-11-07 Impact factor: 4.406
Authors: Denise L Jacobson; Kunjal Patel; Paige L Williams; Mitchell E Geffner; George K Siberry; Linda A DiMeglio; Marilyn J Crain; Ayesha Mirza; Janet S Chen; Elizabeth McFarland; Deborah Kacanek; Margarita Silio; Kenneth Rich; William Borkowsky; Russell B Van Dyke; Tracie L Miller Journal: Pediatr Infect Dis J Date: 2017-02 Impact factor: 2.129
Authors: Charlotte E Lane; Emily A Bobrow; Diuedonne Ndatimana; Gilles F Ndayisaba; Linda S Adair Journal: Matern Child Nutr Date: 2019-01-29 Impact factor: 3.092
Authors: Jennifer Y Chen; Heather J Ribaudo; Sajini Souda; Natasha Parekh; Anthony Ogwu; Shahin Lockman; Kathleen Powis; Scott Dryden-Peterson; Tracy Creek; William Jimbo; Tebogo Madidimalo; Joseph Makhema; Max Essex; Roger L Shapiro Journal: J Infect Dis Date: 2012-10-12 Impact factor: 5.226